BACKGROUND: The significance of troponin elevation and clinical utility of troponin testing in ambulatory patients with coronary artery disease (CAD) have not been examined. We sought to investigate the prevalence and prognostic value of cardiac troponin T (cTnT) elevation in a population with stable CAD. METHODS: We studied 987 patients with stable CAD enrolled in the Heart & Soul study who had plasma cTnT measurements before performing exercise treadmill testing. RESULTS: Of the studied population, 58 patients or 6.2% had detectable cTnT levels, >or=0.01 ng/mL (0.01-0.72 ng/mL). During a mean follow-up period of 4.3 (0.1-6.5) years, 58.6% of participants with detectable cTnT had cardiovascular events compared with 22.5% of those without detectable cTnT (hazard ratio [HR] 3.8, 95% CI 2.6-5.4, P < .001). This association remained strong after adjustment for traditional risk factors and C-reactive protein (HR 2.0, 95% CI 1.3-3.1, P = .002). However, after further adjustment for N-terminal pro-B-type natriuretic peptide and echocardiographic parameters of left ventricular function, cTnT elevation was not an independent predictor of cardiovascular events (HR 1.3, 95% CI, 0.8-2.3, P = .28). CONCLUSIONS: In ambulatory patients with stable CAD, the prevalence of cTnT elevation was 6.2%. Cardiac troponin T elevation detected using the conventional troponin assay was associated with increased risk of adverse cardiovascular outcomes, but its prognostic value was not incremental over N-terminal pro-B-type natriuretic peptide and echocardiographic evidence of cardiac abnormalities.
BACKGROUND: The significance of troponin elevation and clinical utility of troponin testing in ambulatory patients with coronary artery disease (CAD) have not been examined. We sought to investigate the prevalence and prognostic value of cardiac troponin T (cTnT) elevation in a population with stable CAD. METHODS: We studied 987 patients with stable CAD enrolled in the Heart & Soul study who had plasma cTnT measurements before performing exercise treadmill testing. RESULTS: Of the studied population, 58 patients or 6.2% had detectable cTnT levels, >or=0.01 ng/mL (0.01-0.72 ng/mL). During a mean follow-up period of 4.3 (0.1-6.5) years, 58.6% of participants with detectable cTnT had cardiovascular events compared with 22.5% of those without detectable cTnT (hazard ratio [HR] 3.8, 95% CI 2.6-5.4, P < .001). This association remained strong after adjustment for traditional risk factors and C-reactive protein (HR 2.0, 95% CI 1.3-3.1, P = .002). However, after further adjustment for N-terminal pro-B-type natriuretic peptide and echocardiographic parameters of left ventricular function, cTnT elevation was not an independent predictor of cardiovascular events (HR 1.3, 95% CI, 0.8-2.3, P = .28). CONCLUSIONS: In ambulatory patients with stable CAD, the prevalence of cTnT elevation was 6.2%. Cardiac troponin T elevation detected using the conventional troponin assay was associated with increased risk of adverse cardiovascular outcomes, but its prognostic value was not incremental over N-terminal pro-B-type natriuretic peptide and echocardiographic evidence of cardiac abnormalities.
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald Journal: N Engl J Med Date: 1996-10-31 Impact factor: 91.245
Authors: W Frank Peacock; Teresa De Marco; Gregg C Fonarow; Deborah Diercks; Janet Wynne; Fred S Apple; Alan H B Wu Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: J Craig Longenecker; Josef Coresh; Neil R Powe; Andrew S Levey; Nancy E Fink; Alice Martin; Michael J Klag Journal: J Am Soc Nephrol Date: 2002-07 Impact factor: 10.121
Authors: Jart H C Diris; Christian M Hackeng; Jeroen P Kooman; Yigal M Pinto; Wim T Hermens; Marja P van Dieijen-Visser Journal: Circulation Date: 2003-12-22 Impact factor: 29.690
Authors: Alexis L Beatty; Ivy A Ku; Robert H Christenson; Christopher R DeFilippi; Nelson B Schiller; Mary A Whooley Journal: JAMA Intern Med Date: 2013-05-13 Impact factor: 21.873
Authors: Stephen Fenning; Rebecca Woolcock; Kristin Haga; Javaid Iqbal; Keith A Fox; Scott A Murray; Martin A Denvir Journal: PLoS One Date: 2012-04-18 Impact factor: 3.240
Authors: Lena Hinrichs; Simone Maria Mrotzek; Raluca-Ileana Mincu; Julia Pohl; Alina Röll; Lars Michel; Amir Abbas Mahabadi; Fadi Al-Rashid; Matthias Totzeck; Tienush Rassaf Journal: Front Pharmacol Date: 2020-05-19 Impact factor: 5.810
Authors: Anne H Blaes; Aamer Rehman; David M Vock; Xianghua Luo; Mark Menge; Douglas Yee; Emil Missov; Daniel Duprez Journal: Vasc Health Risk Manag Date: 2015-11-24